Nesfatin-1

Nesfatin-1 is an 82-amino acid satiety peptide derived from the N-terminal region of the 396-amino acid precursor protein nucleobindin-2 (NUCB2). Discovered in 2006, it is expressed in the hypothalamus, brainstem, and peripheral tissues including the stomach and adipose tissue. Central nesfatin-1 potently suppresses food intake in a leptin-independent manner, making it a research target for obesity and metabolic disease.

Nesfatin-1 exerts anorexigenic effects predominantly through central (hypothalamic and brainstem) mechanisms. Intracerebroventricular injection suppresses food intake dose-dependently by activating oxytocin neurons in the paraventricular nucleus and modulating melanocortin signaling. Nesfatin-1 also acts on the melanocortin-3/4 receptor system downstream. Peripherally, it is released postprandially from gastric X/A-like cells and may function as a gut-derived satiety signal. Its receptor has not been definitively identified, though GPR3 and NPY-related receptors have been proposed.

Since its discovery in 2006, nesfatin-1 research has grown substantially. Animal studies consistently show that central nesfatin-1 reduces food intake and body weight gain, and that neutralizing antibodies stimulate appetite. Plasma nesfatin-1 levels are altered in obesity, anorexia nervosa, and type 2 diabetes in human studies. Preclinical research suggests cardioprotective effects against ischemia-reperfusion injury. No human interventional trials have been conducted. The receptor and downstream signaling cascade remain incompletely characterized.